Price T Rowe Associates Inc Uro Gen Pharma Ltd. Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
A detailed history of Price T Rowe Associates Inc transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 393,984 shares of URGN stock, worth $4.42 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
393,984
Previous 12,839
2968.65%
Holding current value
$4.42 Million
Previous $164,000
2459.15%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding URGN
# of Institutions
136Shares Held
36MCall Options Held
57.7KPut Options Held
9.8K-
Rtw Investments, LP New York, NY3.83MShares$43 Million0.67% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.93MShares$32.9 Million0.06% of portfolio
-
Menora Mivtachim Holdings Ltd.2.3MShares$25.8 Million0.15% of portfolio
-
Black Rock Inc. New York, NY2.19MShares$24.6 Million0.0% of portfolio
-
Toronto Dominion Bank Toronto, Ontario, A61.75MShares$19.6 Million0.03% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $255M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...